
OmniAb Inc (OABI) Stock Forecast & Price Target
OmniAb Inc (OABI) Analyst Ratings
Bulls say
OmniAb Inc. has demonstrated strong financial performance with first-quarter 2025 revenues of $4.2 million, reflecting a 9% increase year-over-year, coupled with a reduction in net losses to $18.2 million, equating to a loss of $0.17 per share, down from $19.0 million, or $0.19 per share the previous year. The company maintains a solid balance sheet which supports its ongoing operations and strategic initiatives. Additionally, the anticipated near- and long-term R&D catalysts are expected to drive further growth and momentum for OmniAb's shares going forward.
Bears say
OmniAb Inc has experienced a decline in its stock price since the November 2022 merger with Avista Public Acquisition Corporation II, primarily due to adverse market conditions affecting similar transactions and established biotechnology firms. The company has indicated expectations for operating cash burn this year to be lower than that of 2024, yet such guidance raises concerns regarding financial sustainability in the context of ongoing operational costs. Overall, the combination of negative market sentiment and potentially high cash burn rates contributes to a fundamentally negative outlook for OmniAb's stock.
This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.
OmniAb Inc (OABI) Analyst Forecast & Price Prediction
Start investing in OmniAb Inc (OABI)
Order type
Buy in
Order amount
Est. shares
0 shares